...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
Cancer Gene Therapy publication: Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
Posted by:
BearDownAZ
on
Aug 17, 2021 09:47PM
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
Posted by:
BearDownAZ
on
Jul 22, 2021 10:02AM
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Posted by:
BearDownAZ
on
Jul 22, 2021 10:02AM
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
AACR 2021 Poster: COMBINATION OF ZEN-3694 WITH TALAZOPARIB IS A NOVEL THERAPEUTIC APPROACH IN ER POSITIVE BREAST CANCER RESISTANT TO CDK4/6 INHIBITORS, INDEPENDENT OF BRCA STATUS
Posted by:
BearDownAZ
on
Apr 12, 2021 11:13AM
Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020
Posted by:
BearDownAZ
on
Jul 28, 2020 10:29PM